Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
May 18, 2018 • 8:00 AM EDT
Ligand Prices Offering of $650 Million of Convertible Senior Notes
May 16, 2018 • 4:51 PM EDT
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
May 11, 2018 • 9:00 AM EDT
Ligand to Participate in Upcoming Investor Conferences
Jun 19, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
See all events
Jun 6, 2018 • 8:00am EDT
New York, NY
May 30, 2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP on patients' quality of life https://t.co/pGQWEgALRN
CStone Pharmaceuticals initiates two pivotal Phase 2 studies of OmniAb-derived anti-PD-L1 monoclonal antibody CS1001 https://t.co/xsc79IKoWl
Ligand partner Retrophin announces expansion of intellectual property estate for Sparsentan with newly issued U.S.… https://t.co/pFqLFmV0hR